Galanthamine hydrobromide is a reversible, competitive acetylcholinesterase inhibitor primarily prescribed for the treatment of mild to moderate dementia of the Alzheimer’s type, as it helps enhance cholinergic… Read more
Galanthamine hydrobromide is a reversible, competitive acetylcholinesterase inhibitor primarily prescribed for the treatment of mild to moderate dementia of the Alzheimer’s type, as it helps enhance cholinergic neurotransmission. To support the rigorous quality control and analytical requirements of pharmaceutical development, this category provides a comprehensive selection of reference standards, including the active pharmaceutical ingredient, its racemic form, and a range of related substances. Laboratories utilize these high-quality materials to conduct accurate impurity profiling, method validation, and stability testing. By incorporating pharmacopeial and non-pharmacopeial impurities, such as galanthaminone and dihydrogalanthamine, alongside stable isotope labelled compounds, researchers can ensure compliance with regulatory standards. These analytical tools are essential for identifying degradation products and monitoring the chemical integrity of the drug throughout the development process.